CN112755051B - 一种nk细胞的制备及治疗癌症中的应用 - Google Patents
一种nk细胞的制备及治疗癌症中的应用 Download PDFInfo
- Publication number
- CN112755051B CN112755051B CN202110092687.6A CN202110092687A CN112755051B CN 112755051 B CN112755051 B CN 112755051B CN 202110092687 A CN202110092687 A CN 202110092687A CN 112755051 B CN112755051 B CN 112755051B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- cells
- chain variable
- variable region
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
单克隆抗体 | 平衡解离常数 |
4C6单克隆抗体 | 4.27E-11 |
组别 | caspase-3相对表达量 | cleavedcaspase-3相对表达量 |
实验组1 | 0.77±0.06 | 1.31±0.10 |
实验组2 | 0.60±0.05 | 1.57±0.08 |
实验组3 | 0.82±0.04 | 1.20±0.06 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110092687.6A CN112755051B (zh) | 2021-01-25 | 2021-01-25 | 一种nk细胞的制备及治疗癌症中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110092687.6A CN112755051B (zh) | 2021-01-25 | 2021-01-25 | 一种nk细胞的制备及治疗癌症中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112755051A CN112755051A (zh) | 2021-05-07 |
CN112755051B true CN112755051B (zh) | 2021-08-31 |
Family
ID=75706957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110092687.6A Active CN112755051B (zh) | 2021-01-25 | 2021-01-25 | 一种nk细胞的制备及治疗癌症中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112755051B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103333247A (zh) * | 2013-05-30 | 2013-10-02 | 北京东方百泰生物科技有限公司 | 新型抗vegfr2的单克隆抗体及其制备与应用 |
CN109384845A (zh) * | 2017-08-14 | 2019-02-26 | 中国科学院上海生命科学研究院 | 一种cd40单克隆抗体、其制备方法及其应用 |
-
2021
- 2021-01-25 CN CN202110092687.6A patent/CN112755051B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103333247A (zh) * | 2013-05-30 | 2013-10-02 | 北京东方百泰生物科技有限公司 | 新型抗vegfr2的单克隆抗体及其制备与应用 |
CN109384845A (zh) * | 2017-08-14 | 2019-02-26 | 中国科学院上海生命科学研究院 | 一种cd40单克隆抗体、其制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112755051A (zh) | 2021-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112426526B (zh) | 一种nk细胞的制备方法及其在治疗癌症中的应用 | |
CN109400713B (zh) | 新型嵌合抗原受体修饰的t细胞治疗癌症的用途 | |
CN109385403B (zh) | 靶向gpc3的car nk细胞 | |
JP2017127314A (ja) | 抗原特異的t細胞の増殖のための方法 | |
CN108752482B (zh) | 携带截短或未截短的髓样细胞触发性受体信号结构的嵌合抗原受体及其应用 | |
CN111944054B (zh) | 抗bcma的car及其表达载体和应用 | |
WO2023046110A1 (zh) | 联合表达CCR2b的工程化免疫细胞及其制备和应用 | |
CN113402619B (zh) | 一种靶向B7H3共表达IL-21的全人源嵌合抗原受体、iNKT细胞及其用途 | |
US11925662B2 (en) | Compositions and methods of enhancing anti-tumor response using hybrid neutrophils | |
JP2021523090A (ja) | 腫瘍を治療するための方法および組成物 | |
KR20230129979A (ko) | 수지상 세포 활성화 키메라 항원 수용체 및 이의 용도 | |
CN110317822B (zh) | Trop2嵌合抗原受体、其t细胞及其制备方法和用途 | |
KR20230018376A (ko) | 키메라 항원 수용체를 발현하는 바이러스 특이적 면역세포를 사용한 암의 치료 및 예방 | |
CN113214408B (zh) | 一种嵌合抗原受体巨噬细胞及其制备方法和用途 | |
WO2023083192A1 (zh) | 联合表达CCR2b和CD40L的工程化免疫细胞及其制备和应用 | |
CN110055269B (zh) | 人间皮素嵌合抗原受体、其t细胞及其制备方法和用途 | |
JP2024525807A (ja) | 新規キメラ受容体組成物、組換えベクター、細胞およびそれらの応用 | |
CN110713977B (zh) | 一种cd8 t细胞的培养扩增方法 | |
CN108822216B (zh) | 携带截短或未截短的自然细胞毒性受体信号结构的嵌合抗原受体及其应用 | |
CN111944053B (zh) | 抗bcma的car及其表达载体和应用 | |
CN113621077B (zh) | 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞 | |
WO2018205472A1 (zh) | 结合pd-1受体的非抗体结合蛋白及其应用 | |
CN109232740B (zh) | 一种抗pd-l1抗体及其在抗肿瘤治疗中的应用 | |
CN113832102A (zh) | Cd3/cd28/dll4磁珠及其制备方法和应用 | |
CN113117073A (zh) | 免疫细胞联合抗体在治疗癌症中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Xiaobo Inventor after: Cao Fan Inventor after: Zhang Guojun Inventor after: Qi AI Jie Inventor after: Li Shaobo Inventor after: Qi AI Lei Inventor before: Qi Aijie Inventor before: Li Shaobo Inventor before: Qi Ailei |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210813 Address after: 510320 units 401 and 407, 4th floor, No. 5, helix 4th Road, International Biological Island, Guangzhou, Guangdong Applicant after: Guangdong Renda Biotechnology Co.,Ltd. Address before: 1408, 14th floor, building 1, yard 5, Ronghua Middle Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing Applicant before: Beijing Daxi Biotechnology Co., Ltd |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |